VP, Regulatory Policy, Engagement & Intelligence

<div class="content-intro"><p><span style="text-decoration: underline;"><strong><span data-contrast="auto">Mavericks Wanted</span></strong><span data-ccp-props="{&quot;134233117&quot;:true,&quot;134233118&quot;:true,&quot;201341983&quot;:0,&quot;335559740&quot;:240}">&nbsp;</span></span></p> <p><span data-contrast="auto">When was the last time you achieved the impossible? If that thought feels overwhelming, you might want to pause here, but if it sparks excitement...read on</span>&nbsp;<br><span data-contrast="auto"> </span>&nbsp;<br><span data-contrast="auto">In 2015, we pioneered a “moneyball for biotech” approach, pooling projects and promising early-stage research from academia together under one financial umbrella to reduce risk and unleash innovation. This model allows science and small teams of experts to lead the way. We build bridges to groundbreaking advancements in rare&nbsp;disease, and&nbsp;develop life-changing medicines for patients with unmet needs as fast as humanly possible. </span>&nbsp;<br><span data-contrast="auto"> </span>&nbsp;<br><span data-contrast="auto">Together we define white space, push boundaries, and empower people to solve problems. If you're someone who defies convention, join us and work alongside some of the most respected minds in the industry. Together, we'll&nbsp;ask&nbsp;"why not?" and help reengineer the future of biopharma. At BridgeBio, we value curiosity and experimentation—including the ethical &amp; thoughtful use of AI to improve clarity, speed, and quality of work.</span><span data-ccp-props="{&quot;134233117&quot;:true,&quot;134233118&quot;:true,&quot;201341983&quot;:0,&quot;335559740&quot;:240}">&nbsp;</span></p></div><h3><strong>Location: </strong>Washington, DC</h3> <p><strong>Work Schedule: </strong>Hybrid – minimum 3 days per week in office</p> <p><strong>&nbsp;</strong></p> <p><strong><u>About BridgeBio</u></strong></p> <p><strong>BridgeBio</strong> is a biopharmaceutical company founded to discover, create, test, and deliver transformative medicines to treat patients who suffer from genetic diseases and cancers with clear genetic drivers. We bridge the gap between remarkable advancements in genetic science in academic institutions and the delivery of meaningful medicines to patients. Founded in 2015, the company has built a portfolio of 20+ drug development programs ranging from preclinical to late-stage development in multiple therapeutic areas including genetic de